Guo Teng, Du Li-Ying, Liu Ming-Feng, Zhou Xia-Jin, Chen Xin-Ran
Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang 050011, Hebei Province, China.
World J Clin Cases. 2025 Jun 6;13(16):102866. doi: 10.12998/wjcc.v13.i16.102866.
Plasma concentration monitoring is crucial for optimizing vancomycin use, particularly in patients in the intensive care unit (ICU). However, the reference interval for vancomycin plasma concentration remains undetermined.
To evaluate the correlations of area under the curve (AUC) and trough concentration (C) with efficacy and nephrotoxicity in patients in the ICU.
A total of 103 patients treated with vancomycin for methicillin-resistant infections were analyzed in this study. The associations of clinicodemographic characteristics (including sex, age, weight, infection sites, main etiologies of ICU cases, comorbidities, acute physiological chronic health evaluation II score, and mechanical ventilation) and pharmacokinetics (daily dose, C, AUC, and AUC/minimum inhibitory concentration) with efficacy and nephrotoxicity of vancomycin were evaluated with univariate and multivariate logistic regression analyses. AUC was calculated using VCM-TDM software based on vancomycin population pharmacokinetics and Bayesian feedback method.
C over 9.4 μg/mL and AUC exceeding 359.6 μg × hour/mL indicated good efficacy against infection. C below 14.0 μg/mL predicted no significant nephrotoxicity.
In this study, the effective and safe concentration interval for vancomycin in patients in the ICU was C 9.4-14.0 μg/mL. Close attention should be paid to adverse effects and renal function during vancomycin treatment.
血浆浓度监测对于优化万古霉素的使用至关重要,尤其是在重症监护病房(ICU)的患者中。然而,万古霉素血浆浓度的参考区间仍未确定。
评估曲线下面积(AUC)和谷浓度(C)与ICU患者疗效和肾毒性的相关性。
本研究共分析了103例接受万古霉素治疗耐甲氧西林感染的患者。通过单因素和多因素逻辑回归分析,评估临床人口统计学特征(包括性别、年龄、体重、感染部位、ICU病例的主要病因、合并症、急性生理与慢性健康状况评估II评分和机械通气)以及药代动力学(每日剂量、C、AUC和AUC/最低抑菌浓度)与万古霉素疗效和肾毒性的相关性。AUC使用基于万古霉素群体药代动力学和贝叶斯反馈方法的VCM-TDM软件计算。
C超过9.4μg/mL且AUC超过359.6μg×小时/mL表明对感染有良好疗效。C低于14.0μg/mL预示无明显肾毒性。
在本研究中,ICU患者万古霉素的有效且安全浓度区间为C 9.4 - 14.0μg/mL。万古霉素治疗期间应密切关注不良反应和肾功能。